GetTopicDetailResponse(id=d63b120168b5, topicName=抗體偶聯藥, introduction=, content=AZD8205 抗體偶聯藥, image=null, comments=0, allHits=419, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Tue Oct 15 17:30:21 CST 2024, time=2024-10-15, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=496960, tagList=[TagDto(tagId=496960, tagName=抗體偶聯藥)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2231807, encodeId=0216223180e2f, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=d63b120168b5' target=_blank style='color:#2F92EE;'>#抗體偶聯藥#</a>, objectTitle=HER2陰性三陰乳腺癌，使用DS-8201后全部病灶全消失，原因是漏檢了？, objectType=article, longId=847736, objectId=207984e736e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220813/1660373278819_8252897.webp, objectUrl=/article/show_article.do?id=207984e736e9, replyNumber=0, likeNumber=51, createdTime=2024-10-20, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=207984e736e9, moduleTitle=HER2陰性三陰乳腺癌，使用DS-8201后全部病灶全消失，原因是漏檢了？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=207984e736e9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2231069, encodeId=165e2231069e0, content=<a href='/topic/show?id=723112016ec0' target=_blank style='color:#2F92EE;'>#AZD8205#</a> <a href='/topic/show?id=d63b120168b5' target=_blank style='color:#2F92EE;'>#抗體偶聯藥#</a>, objectTitle=2024年ESMO：抗體偶聯藥AZD8205 的首次人體臨床試驗數據公布，多個腫瘤類型迎來新希望！, objectType=article, longId=846435, objectId=0ea88464353b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401014/1728901409183_8538692.png, objectUrl=/article/show_article.do?id=0ea88464353b, replyNumber=0, likeNumber=50, createdTime=2024-10-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0ea88464353b, moduleTitle=2024年ESMO：抗體偶聯藥AZD8205 的首次人體臨床試驗數據公布，多個腫瘤類型迎來新希望！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0ea88464353b)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-10-15發(fā)表于上海
